



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

MAY - 5 1998

Charles Van Horn
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
1300 I Street, N.W.
Washington, D.C. 20005-3315

In Re: Patent Term Extension
Application for
U.S. Patent No. 4,689,339

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,689,339, which claims the animal drug product ANTISEDAN® (atipamezole hydrochloride), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 1,719 days.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue a certificate of extension, under seal, for a period of 1,719 days.

The period of extension has been calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of July 18, 1997 (62 Fed. Reg. 38563). Under 35 U.S.C. § 156(c):

$$\begin{aligned} \text{Period of Extension} &= \frac{1}{2} (\text{Testing Phase}) + \text{Approval Phase} \\ &= \frac{1}{2} (1,429) + 1,234 \\ &= 1,949 \text{ days} \end{aligned}$$

Since the regulatory review period began April 24, 1989, after the patent issue date (August 25, 1987), the entire period has been considered in the above determination. No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

However, the 14 year exception of 35 U.S.C. § 156(c)(3) operates to limit the term of the extension in the present situation because it provides that the period remaining in the term of the patent measured from the date of approval of the approved product plus any patent term extension cannot exceed fourteen years. The period of extension calculated above, 1,949 days, would extend the patent from November 21, 2005 to March 23, 2011, which is beyond the 14-year limit (14 years after the approval date is August 6, 2010). Accordingly, the period of extension is the number of days to extend the term of the patent from its original expiration date, November 21, 2005 to and including August 6, 2010, or 1,719 days.

The limitations of 35 U.S.C. § 156(g)(6) do not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.	:	4,689,339
Granted	:	August 25, 1987
Original Expiration Date ¹	:	November 21, 2005
Applicant	:	Arto J. Karjalainen et al.
Owner of Record	:	Orion-Yhtymä Oy
Title	:	4-Dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, Useful to Block α_2 -adrenergic Receptors
Classification	:	514/396
Product Trade Name	:	ANTISEDAN® (atipamezole hydrochloride)
Term Extended	:	1,719 days
Expiration Date of Extension	:	August 6, 2010

Any correspondence with respect to this matter should be addressed as follows:

By mail: Assistant Commissioner for Patents
Box Patent Ext.
Washington, D.C. 20231

By FAX: (703) 308-6916
Attn: Special Program Law Office

By hand: One Crystal Park, Suite 520
2011 Crystal Drive
Arlington, VA

¹Subject to the provisions of 35 U.S.C. § 41(b).

Telephone inquiries related to this determination should be directed to the undersigned at (703) 306-3159.



Karin Tyson
Senior Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: ANTISEDAN®
FDA Docket No.: 96E-0439